A Pivotal Phase II 90-day study of BTI-410 in Type 2 diabetes patients

Trial Profile

A Pivotal Phase II 90-day study of BTI-410 in Type 2 diabetes patients

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Human proislet peptide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Boston Therapeutics
  • Most Recent Events

    • 11 Apr 2018 New trial record
    • 27 Mar 2018 According to a Boston Therapeutics media release, this trial is planned to initiate during the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top